The recent approval of a prostate cancer vaccine has renewed hope for anticancer immunotherapies. However, the immunosuppressive tumor microenvironment may limit the effectiveness of current immunotherapies. Antiangiogenic agents have the potential to modulate the tumor microenvironment and improve immunotherapy, but they often are used at high doses in the clinic to prune tumor vessels and paradoxically may compromise various therapies. Here, we demonstrate that targeting tumor vasculature with lower vascular-normalizing doses, but not high antivascular/antiangiogenic doses, of an anti-VEGF receptor 2 (VEGFR2) antibody results in a more homogeneous distribution of functional tumor vessels. Furthermore, lower doses are superior to the high doses in polarizing tumor-associated macrophages from an immune inhibitory M2-like phenotype toward an immune stimulatory M1-like phenotype and in facilitating CD4 + and CD8 + T-cell tumor infiltration. Based on this mechanism, scheduling lower-dose anti-VEGFR2 therapy with T-cell activation induced by a whole cancer cell vaccine therapy enhanced anticancer efficacy in a CD8 + T-cell-dependent manner in both immune-tolerant and immunogenic murine breast cancer models. These findings indicate that vascular-normalizing lower doses of anti-VEGFR2 antibody can reprogram the tumor microenvironment away from immunosuppression toward potentiation of cancer vaccine therapies. Given that the combinations of high doses of bevacizumab with chemotherapy have not improved overall survival of breast cancer patients, our study suggests a strategy to use antiangiogenic agents in breast cancer more effectively with active immunotherapy and potentially other anticancer therapies.
The chemokine CXCL12 and its receptor CXCR4 are expressed widely in human
cancers including ovarian cancer, where they are associated with disease
progression at the levels of tumor cell proliferation, invasion, and
angiogenesis. Here we used an immunocompetent mouse model of intraperitoneal
papillary epithelial ovarian cancer to demonstrate that modulation of the
CXCL12/CXCR4 axis in ovarian cancer has multimodal effects on tumor pathogenesis
associated with induction of antitumor immunity. siRNA-mediated knockdown of
CXCL12 in BR5-1 cells that constitutively express CXCL12 and CXCR4 reduced cell
proliferation in vitro and tumor growth in vivo. Similarly, treatment of
BR5-1-derived tumors with AMD3100, a selective CXCR4 antagonist, resulted in
increased tumor apoptosis and necrosis, reduction in intraperitoneal
dissemination, and selective reduction of intratumoral FoxP3+ regulatory T-cells
(T-regs). Compared to controls, CXCR4 blockade greatly increased T cell-mediated
antitumor immune responses, conferring a significant survival advantage to
AMD3100-treated mice. In addition, the selective effect of CXCR4 antagonism on
intratumoral T regulatory cells was associated with both higher CXCR4 expression
and increased chemotactic responses to CXCL12, a finding that was also confirmed
in a melanoma model. Together, our findings reinforce the concept of a critical
role for the CXCL12/CXCR4 axis in ovarian cancer pathogenesis, and they offer a
definitive preclinical validation of CXCR4 as a therapeutic target in this
disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.